Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry

Biomedical Chromatography

Volumn 25, Issue 11, 2011, Pages 1208-1214

  Shin, Beom Soo ^a   Kim, Tae Hwan ^a   Paik, Soo Heui ^b   Chi, Yong Ha ^b   Lee, Joo Han ^b   Tan, Hyun Kwang ^b   Choi, Yohan ^c   Kim, Minki ^c   Yoo, Sun Dong ^c  

^a Catholic University of Daegu   (South Korea)

^b Boryung Pharm Co Ltd   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

aAngiotensin II receptor blocker; BR A 557; BR A 657; Fimasartan; LC MS MS

Indexed keywords

BODY FLUIDS; BROMINE COMPOUNDS; LIQUID CHROMATOGRAPHY; METABOLITES; RATS;

AANGIOTENSIN II RECEPTOR BLOCKER; ACTIVE METABOLITES; BR-A-557; BR-A-657; FIMASARTAN; LC-MS-MS; LC.MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; RAT PLASMA; SIMULTANEOUS DETERMINATIONS;

MASS SPECTROMETRY;

ACETONITRILE; ANTIHYPERTENSIVE AGENT; BR A 557; BR A 563; DESULFOFIMASARTAN; DRUG METABOLITE; FIMASARTAN; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; PYRIMIDINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG DETERMINATION; ELUTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRECIPITATION; RAT; TANDEM MASS SPECTROMETRY; ANIMAL; BLOOD; CHEMISTRY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT; STATISTICAL MODEL;

RATTUS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CHROMATOGRAPHY, LIQUID; LINEAR MODELS; MALE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TETRAZOLES;

EID: 80053602802     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1592     Document Type: Article

References (10)

1. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103: 904-912.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT and Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure - the JNC 7 Report. Journal of the American Medical Association 2003; 289: 2560-2572.
3. Jang KJ, Lee KH, Yoo BW, Lee JH, Kim JH and Kim SL. Antihypertensive effects of a novel All receptor antagonist, BR-A-657, in various hypertensive models. Japanese Journal of Pharmacology 1999; 79(suppl.): 195P.
4. Kim JW, Kim BR, Shim JH, Yoon SH, Cho JY, Shin SG, Yu KS and Jang IJ. Pharmacokinetic interaction between a novel angiotensin II receptor blocker, fimasartan, and hydrochlorothiazide in healthy volunteers. Clinical Pharmacology and Therapeutics 2010; 87(suppl.): S53-S54.
5. Lane A, Kleinermanns D, Bryson S, Lee J, Tan H and Chi Y. Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clinical Pharmacology and Therapeutics 2005a; 77(suppl.): P58-P58.
6. Lane A, Engmann E, Bryson S, Lee J, Tan H and Chi Y. Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, and angiotensin II (AII) antagonist. Clinical Pharmacology and Therapeutics 2005b; 77(suppl.): P59-P59.
7. 14C] BR-A-657) following oral or intravenous administration to rats. Drug Metabolism Review 2006; 38(suppl.): 154-155.
8. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HAJ and Zanchetti A. Guidelines for the management of arterial hypertension - the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2007; 28: 1462-1536.
9. Matchar DB, McCrory DC., Orlando, LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP and, Gray RN. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Annals of Internal Medicine 2008; 148: 16-29.
10. Smith DHG. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clinical Therapeutics 2002; 24: 1484-1501.